This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can’t ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy ...

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...

The 5:2 diet effectively reduces weight, BMI, and LDL while improving cardiometabolic health in patients with overweight or obesity, per a meta-analysis.

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...

Though high cholesterol may contribute to the risk of developing Alzheimer’s disease or a related dementia (ADRD), taking a ...

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting ...